Clinical trial for Dry Age-related Macular Degeneration
Official title A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
ClinicalTrials.gov ID: NCT06557460
What this study is testing
- What it's testing
- The study aims to see if the implant is safe and if it can slow or improve the loss of vision caused by geographic atrophy.
- Who it's for
- Adults with advanced dry age‑related macular degeneration that has formed geographic atrophy affecting the central vision.
- What's involved
- Participants will have one eye surgically implanted with the CPCB‑RPE1 device or undergo a simulated (sham) procedure, followed by regular eye exams and imaging visits.
- Time commitment
- The trial lasts about a year with several follow‑up visits after the single surgery.
- Phase 2: a mid-size study of how well it works
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 to 90
You may be able to join if
- Age 55 to 90 years of age (inclusive), presenting with geographic atrophy involving the fovea in advanced, age-related, dry AMD.
- Clinical findings consistent with advanced dry AMD with evidence of one or more areas of ≥4.0mm2 but not exceeding 15.0 mm2 of geographic atrophy...
- Geographic atrophy defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, or FAF.
- The best-corrected visual acuity (BCVA) of the eye to receive the implant will be ≥20/200 (35 EDTRS letters) to 20/63 (60 EDTRS letters) inclusive.
- Medically suitable to undergo pars plana vitrectomy and the surgical implant procedure, including being able to position post-operatively and use...
See the full eligibility criteria
- Age 55 to 90 years of age (inclusive), presenting with geographic atrophy involving the fovea in advanced, age-related, dry AMD.
- Clinical findings consistent with advanced dry AMD with evidence of one or more areas of ≥4.0mm2 but not exceeding 15.0 mm2 of geographic atrophy involving the fovea.
- Geographic atrophy defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, or FAF.
- The best-corrected visual acuity (BCVA) of the eye to receive the implant will be ≥20/200 (35 EDTRS letters) to 20/63 (60 EDTRS letters) inclusive.
- Medically suitable to undergo pars plana vitrectomy and the surgical implant procedure, including being able to position post-operatively and use post-operative medications as required.
- Medically suitable for general anesthesia or monitored intravenous sedation, if needed.
- Pseudophakic in the study eye, to remove the risk of cataract formation following vitrectomy.
- Participants also must be willing and able to provide written, signed informed consent for this study.
- Participants able to complete the baseline microperimetry retinal sensitivity testing.
- On baseline microperimetry, participants must have ≥5 spots in the perilesional region with a retinal sensitivity between 3 and 17 Db.
The study team makes the final eligibility decision.
Where it is enrolling
- Huntington Beach, California, United States
- Los Angeles, California, United States
- Lemont, Illinois, United States
- Austin, Texas, United States
- The Woodlands, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Huntington Beach, California, United States; Los Angeles, California, United States; Lemont, Illinois, United States; Austin, Texas, United States; The Woodlands, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.